A chiral silica nanoparticle, its preparation method and application

By preparing chiral silica nanoparticles and binding them with EIF4A2 protein to induce stress particle assembly, the problem of efficient activation of nanomaterials in immune regulation was solved, achieving efficient and specific immune activation and pro-inflammatory cytokine secretion, and providing a clear immune activation mechanism.

CN123061965APending Publication Date: 2026-11-10中国人民解放军总医院第八医学中心
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611274643.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-21
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing nanomaterials lack a technical solution for efficiently activating the immune system by relying on their own chiral configuration in terms of immune regulation, and exogenous immune stimulation molecular strategies suffer from high cost, complexity, and non-specific side effects.

Method used

By preparing chiral silica nanoparticles, their chiral structure specifically binds to the EIF4A2 protein, inducing stress particle assembly and achieving immune activation.

Benefits of technology

It achieves efficient and specific immune activation independent of exogenous molecules, significantly promotes the maturation of dendritic cells and macrophages, induces the secretion of pro-inflammatory cytokines, and provides a clear immune activation mechanism and efficient immune regulation effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123061965A_ABST
    Figure CN123061965A_ABST
Patent Text Reader

Abstract

This invention discloses a chiral silica nanoparticle, its preparation method, and its applications. The preparation method includes: using hexadecyltrimethylammonium bromide as a structure-directing agent, and L-ascorbic acid glucoside, D-ascorbic acid glucoside, or a racemic mixture thereof as chiral inducers, dissolving them in an alkaline aqueous solution, adding an organic phase to form a biphase system, then adding tetraethyl orthosilicate, reacting at 50-80°C for 12-24 hours, followed by centrifugation, washing, drying, and calcination at 500-800°C to obtain chiral silica nanoparticles with a mesoporous structure. This invention reveals for the first time that these nanoparticles inhibit the function of EIF4A2 protein through chiral-dependent binding, induce stress granule assembly, and thereby activate dendritic cells and macrophages, promoting the secretion of pro-inflammatory cytokines and the upregulation of co-stimulatory molecules and MHC-II molecules, with the D-chiral configuration showing the best immune activation effect. The nanoparticles can be used to prepare immune activators, vaccine adjuvants, or antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of nanomaterials and immunotherapy technology, and in particular to a chiral silica nanoparticle, its preparation method, and its application. Background Technology

[0002] Chirality, as a spatial property of molecular structure, plays a crucial role in life activities. Natural biological systems, such as enzymes, receptors, and ion channels, exhibit a high degree of selective recognition of chiral molecules. In recent years, with the rapid development of nanotechnology and materials science, researchers have discovered that incorporating chiral features into nanomaterials can endow them with unique physicochemical properties and biological effects, providing new insights for the development of novel biomedical materials.

[0003] Silica nanoparticles have been widely used in drug delivery, bioimaging, and catalysis due to their excellent biocompatibility, chemical stability, ease of functionalization, and mature synthesis processes. Mesoporous silica nanoparticles (MSNs) possess high specific surface area, large pore volume, and tunable pore size, making them particularly suitable as drug carriers. However, traditional research on silica nanomaterials has mainly focused on the regulation of size, morphology, and surface chemistry. Research on the construction of their chiral conformations and their specific recognition and regulatory functions in biological systems, especially the precise regulation of the immune system, remains insufficient.

[0004] While some existing technologies have reported attempts to synthesize chiral mesoporous silica using chiral templates, most focus on its chiral optical properties or catalytic performance. However, systematic research and elucidation regarding its role as an immunomodulator, activating immune cells through specific molecular mechanisms, particularly its specific targets and signaling pathways in antigen-presenting cells (APCs) such as dendritic cells (DCs), are lacking. Currently, the immunoadjuvant function of nanomaterials largely relies on their passive targeting or sustained-release effects as delivery carriers, or on surface-modified immunostimulatory molecules (such as CpG and lipopolysaccharides). This strategy, dependent on exogenous immunostimulatory molecules, suffers from high costs, complex preparation, and potential non-specific immune side effects. Therefore, developing nanomaterials that can efficiently and specifically activate the immune system solely through their own physicochemical properties (especially chiral configuration) without relying on exogenous biomolecules has significant scientific importance and application prospects.

[0005] Furthermore, stress granules (SGs), as membraneless organelles formed in the cytoplasm of eukaryotic cells in response to external stresses (such as oxidative stress, heat shock, and viral infection), are receiving increasing attention for their role in regulating cell survival, gene expression, and immune responses. However, there is currently no mature technical solution for how to actively and controllably induce stress granule formation through exogenous nanomaterials and utilize them to activate the innate immune system.

[0006] Based on this, the present invention proposes and verifies for the first time a new strategy for precise and efficient immune activation by targeting the EIF4A2 protein with chiral silica nanoparticles to induce stress particle assembly. Summary of the Invention

[0007] In view of this, one object of the present invention is to provide silica nanoparticles with a chiral structure that can specifically bind to EIF4A2 protein and induce stress particle formation, and a method for preparing the same. Another object of the present invention is to provide the application of said nanoparticles in the preparation of immune activators or vaccine adjuvants.

[0008] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides a method for preparing chiral silica nanoparticles, comprising the following steps: (1) Preparation of aqueous solution: Dissolve the structure directing agent and chiral inducing agent in deionized water, stir until completely dissolved, and adjust the pH of the solution to alkaline; (2) Constructing a two-phase reaction system: Add an organic phase to the above aqueous solution to form a two-phase system; (3) Adding a silicon source: Under stirring conditions, add a silicate ester compound as a silicon source to the two-phase system and react at 50-80℃ for 12-24 hours; (4) Post-processing: After the reaction is completed, the product is collected by centrifugation, washed, dried, and finally the organic template is removed by calcination to obtain the chiral silica nanoparticles.

[0009] Preferably, in step (1), the structure directing agent is hexadecyltrimethylammonium bromide (CTAB); the chiral inducing agent is L-ascorbate glucoside (L-AG) or D-ascorbate glucoside (D-AG), or a racemic mixture thereof (DL-AG).

[0010] Preferably, in step (2), the organic phase is at least one of cyclohexane, n-hexane, or toluene.

[0011] Preferably, in step (3), the silicate compound is tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS); the reaction temperature is 50-80℃, preferably 60℃; and the reaction time is 12-24 hours.

[0012] Preferably, in step (4), the calcination temperature is 500-800℃, preferably 700℃, and the calcination time is 4-8 hours, in order to remove the organic template and fix the chiral mesoporous structure.

[0013] Secondly, the present invention provides chiral silica nanoparticles prepared by the above preparation method.

[0014] Preferably, the chiral silica nanoparticles have a mesoporous structure, a particle size of 200-300 nm, a polydispersity index (PDI) of less than 0.2, and an absolute value of the zeta potential greater than 30 mV.

[0015] Preferably, the chiral silica nanoparticles exhibit a mirror-symmetric Cotton effect in circular dichroism (CD), confirming their chiral optical activity.

[0016] Thirdly, the present invention provides the application of chiral silica nanoparticles in the preparation of immune activators.

[0017] Preferably, the chiral silica nanoparticles inhibit the function of EIF4A2 protein through chirality-dependent binding, promoting the assembly of intracellular stress granules and thereby activating antigen-presenting cells. The antigen-presenting cells are dendritic cells or macrophages. Immune activation is manifested by increased secretion of pro-inflammatory cytokines and / or upregulation of cell surface co-stimulatory molecules and major histocompatibility complex II (MHC-II) expression.

[0018] Preferably, the pro-inflammatory cytokines include at least one of IL-6, IL-1β, TNF-α, IL-12, and IL-18; the cell surface co-stimulatory molecules include CD80 and / or CD86.

[0019] Fourthly, the present invention provides the use of the chiral silica nanoparticles in the preparation of medicaments for treating and / or preventing tumors.

[0020] Fifthly, the present invention provides a vaccine adjuvant or immunotherapy drug comprising the chiral silica nanoparticles.

[0021] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention reveals for the first time a novel mechanism by which the innate immune system can be efficiently activated solely through the chiral configuration of nanomaterials, without relying on exogenous immune stimulating molecules.

[0022] 2. This invention is the first to discover and verify that the EIF4A2 protein is a chirality-dependent binding target of chiral silica nanoparticles, and elucidates the complete signaling pathway of "chirality recognition - EIF4A2 inactivation - stress particle assembly - immune activation", providing a clear mechanism of action for the immune application of chiral nanomaterials.

[0023] 3. The chiral silica nanoparticles prepared by this invention, especially the D-chiral configuration, have excellent immune activation efficiency, can significantly promote the maturation of dendritic cells and macrophages, and induce the secretion of strong pro-inflammatory cytokines.

[0024] 4. The preparation method of the material of this invention is mature, highly controllable, easy to scale up for production, and has high prospects for clinical translation. Attached Figure Description

[0025] Figure 1 This is a schematic diagram illustrating the synthesis and characterization of chiral silica nanoparticles prepared according to an embodiment of the present invention.

[0026] Figure 2 Flow cytometry of immune-activated DC cells prepared by chiral silica nanoparticles in an embodiment of the present invention.

[0027] Figure 3 Figure showing the results of chiral silica nanoparticles stimulating BMDCs to secrete multiple pro-inflammatory factors.

[0028] Figure 4 This is a map showing the intracellular uptake and localization of chiral silica.

[0029] Figure 5 Fluorescence image of stress particles generated from chiral silica nanoparticles.

[0030] Figure 6 This represents the results of co-localization of chiral silica nanoparticles and EIF4A2 protein within DC2.4 cells.

[0031] Figure 7 This is the result of immunoprecipitation of chiral silica nanoparticles with cell lysates.

[0032] Figure 8 Recombinant EIF4A2 protein solution with different chiral silica nanoparticles.

[0033] Figure 9 The results represent the binding free energies of silica nanoparticles with different chiralities to EIF4A2.

[0034] Figure 10 This is a fluorescence image of DC cells after G3BP1 mutation. Detailed Implementation

[0035] The present invention will be further described below with reference to the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and should not be used to limit the scope of protection of the present invention.

[0036] This invention provides an immune-activating nanomaterial based on chiral configuration regulation, its preparation method, and its application, which are described in detail below through specific embodiments.

[0037] Example 1: Preparation of D-chiral silica nanoparticles (D-CSNPs) This embodiment provides a method for preparing D-chiral silica nanoparticles, such as... Figure 1 As shown in a, the steps include: (1) Preparation of aqueous phase: Weigh 0.5 g CTAB and 0.1 g D-AG, dissolve them in 60 mL deionized water, stir in a 40℃ water bath until completely dissolved, then add 0.5 mL NaOH solution (2 M) and adjust the pH to 8.0.

[0038] (2) Construction of the two-phase system: Add 20 mL of cyclohexane to the above aqueous phase and continue stirring for 30 minutes to form a stable oil-water two-phase system.

[0039] (3) Addition of silicon source and reaction: Add 0.5 mL of TEOS dropwise under vigorous stirring and keep the reaction at 60℃ for 24 hours.

[0040] (4) Post-treatment: After the reaction was completed, the white precipitate was collected by centrifugation, washed three times with deionized water and ethanol, and dried under vacuum at 60°C overnight. The dried powder was placed in a muffle furnace and heated to 700°C at a heating rate of 2°C / min for 6 hours to remove CTAB and chiral template agent, thus obtaining D-chiral silica nanoparticles.

[0041] Example 2: Preparation of L-chiral silica nanoparticles (L-CSNPs) This embodiment provides a method for preparing L-chiral silica nanoparticles, which differs from Example 1 only in that the chiral inducer D-AG is replaced with an equimolar amount of L-AG, while the remaining steps and conditions are exactly the same as in Example 1.

[0042] Example 3: Preparation of racemic chiral silica nanoparticles (Rac-CSNPs) This embodiment provides a method for preparing racemic chiral silica nanoparticles, which differs from Example 1 only in that the chiral inducer D-AG is replaced with an equimolar amount of DL-AG (a racemic mixture of D-AG and L-AG), while the remaining steps and conditions are exactly the same as in Example 1.

[0043] Example 4: Preparation of chiral silica nanoparticles (comparative example) This embodiment provides a method for preparing non-chiral silica nanoparticles, which differs from Example 1 only in that no chiral inducing agent is added, while the remaining steps and conditions are exactly the same as in Example 1.

[0044] Performance Characterization 1. Morphological and structural characterization The products prepared in Examples 1-3 were observed using transmission electron microscopy (TEM) and scanning electron microscopy (SEM). The results are as follows: Figure 1 As shown in c, the obtained nanoparticles all exhibit a regular spherical morphology, with a clear radial mesoporous structure on the surface, and uniform particle size distributed in the range of 200-300 nm. 2. Chiral optical activity detection The chiral optical activity of the products prepared in Examples 1-3 was detected using a circular dichroism chromatograph (CD). The results are as follows: Figure 1 As shown in b, D-CSNPs exhibit a positive Cotton effect in the UV-Vis region, while L-CSNPs exhibit a mirror-symmetric negative Cotton effect, and Rac-CSNPs do not show a significant CD signal. These results confirm that the present invention successfully prepared optically active chiral silica nanoparticles, and that their chirality originates from the material's own helical mesoporous structure rather than residual organic molecules.

[0045] 3. Evaluation of in vitro immune activation effect The three types of chiral silica nanoparticles prepared in Examples 1-3 were co-incubated with bone marrow-derived dendritic cells (BMDCs) and RAW 264.7 macrophages for 24 hours (concentration 100 μg / mL). Cytokine secretion levels in the culture supernatant were detected by ELISA, and cell surface activation marker expression levels were detected by flow cytometry. Results are as follows: Figure 2 , 3 As shown, compared with the control group, all three chiral nanoparticles stimulated BMDCs to secrete multiple pro-inflammatory factors such as IL-6, IL-1β, TNF-α, IL-12, and IL-18, and upregulated the expression of CD80, CD86, and MHC-II. The above immune activation effects showed a clear chiral-dependent trend: D-CSNPs group > L-CSNPs group > Rac-CSNPs group > control group. This indicates that D-chiral silica nanoparticles possess the strongest immune activation ability.

[0046] 4. Intracellular localization of chiral silica nanoparticles To investigate whether chiral silica nanoparticles can be internalized by dendritic cells, their spatiotemporal distribution dynamics within dendritic cells, and the cellular basis of their interaction with the intracellular protein EIF4A2, we co-incubated Cy5.5 fluorescently labeled dextrorotatory silica nanoparticles with dendritic cells and performed time-series imaging using laser confocal microscopy from 1 to 12 h to observe the material internalization and intracellular transport processes. Results ( Figure 4The results showed that the material was mainly adsorbed onto the cell membrane surface within 1 h; at 2 h, a large amount of material underwent endocytosis and exhibited strong co-localization with lysosomes (labeled by LysoTracker); from 4 to 6 h, the material gradually escaped from the lysosomes and accumulated in the cytoplasm and perinuclear region; at 8 h, the material was widely distributed in the cytoplasm; at 12 h, the cell state declined, and the material remained intracellular. These results indicate that chiral silica nanoparticles, after co-incubation with dendritic cells for 2 h, enter dendritic cells via the endocytosis-lysosome pathway, and escape to the cytoplasm and accumulate in the perinuclear region at approximately 6 h. This spatiotemporal dynamic characteristic provides the necessary spatiotemporal conditions and cellular evidence for the direct binding of the material to the EIF4A2 protein in the cytoplasm.

[0047] 4. Molecular mechanism research To elucidate the molecular mechanism of chiral-dependent immune activation, the present invention conducted the following verification experiments: (1) Affinity purification and mass spectrometry identification: BMDC cell lysates were incubated with L-CSNPs and D-CSNPs for pull-down experiments, and the eluted binding proteins were identified by LC-MS / MS. Eukaryotic translation initiation factor 4A2 (EIF4A2) was significantly enriched in the D-CSNPs binding proteome, indicating that EIF4A2 is a key target molecule mediating the efficient immune activation of D-chiral nanoparticles.

[0048] (2) Intracellular colocalization: Immunofluorescence assay results showed that Cy5.5-labeled C-SNPs could be effectively internalized by DC2.4 cells and significantly colocalized with EIF4A2 protein in the cytoplasm, providing direct evidence for their direct interaction within the cell. Figure 6 (As shown).

[0049] (3) Co-immunoprecipitation (Co-IP): To verify whether chiral silica nanoparticles can specifically bind to EIF4A2 protein in dendritic cells and its chirality-dependent binding, this study used a pull-down combined with Western blotting experiment. Levo-, dextro-, and racemic silica nanoparticles were co-incubated with DC cell lysate, and the enrichment of EIF4A2 in the supernatant (unbound group) and the precipitate (bound group) was detected. The results showed that in the unbound group, the dextro-group had the least amount of EIF4A2 remaining in the supernatant, followed by the levo-group, while the racemic group was similar to the control group. In the bound group, the dextro-group had the strongest EIF4A2 enrichment in the precipitate, followed by the levo-group, while the racemic group and the control group were at background levels. These results indicate that chiral silica nanoparticles have a direct and chirality-dependent specific binding to EIF4A2 protein, with the binding ability showing a trend of strongest dextro-group binding, followed by levo-group binding, and no significant binding in the racemic group. These results provide direct biochemical evidence for the molecular mechanism by which chiral materials regulate dendritic cell function through binding to EIF4A2. Figure 7 (As shown).

[0050] (4) Isothermal titration calorimetry (ITC): The purified recombinant EIF4A2 protein solution was titrated with suspensions of different chiral C-SNPs. The results are as follows: Figure 8 As shown, D-CSNPs have the smallest dissociation constant (Kd) with EIF4A2, indicating that they have the strongest binding affinity, which confirms the chiral selectivity of this interaction.

[0051] (5) Molecular dynamics simulations: 100 ns simulations were performed on the complex systems of L-, D-, and Rac-CSNPs with EIF4A2. The MM / PBSA binding free energy calculations showed that the D-CSNPs-EIF4A2 complex had the lowest binding free energy and the highest stability. Figure 9 As shown in the figure, this is consistent with the ITC results.

[0052] (6) To investigate the specific role of eIF4A helicase activity in stress granule formation and its regulatory relationship with G3BP protein, this study used wild-type dendritic cells and G3BP1 and G3BP2 double knockout dendritic cells. Arsenite was treated alone, combined with an eIF4A inhibitor, combined with arsenite and apatamine A (Pat), which inhibits eIF4A translation but enhances ribonucleic acid binding activity, and combined with adenosine triphosphate depletion. Stress granule formation was detected using PABPC1 immunofluorescence assay. Results ( Figure 10The results showed that stress granule formation rates were close to 100% under all treatment conditions in wild-type cells. In double knockout cells, no stress granules formed when treated with arsenite alone, but the formation rate significantly recovered to approximately 80% to 90% after treatment with arsenite combined with an eIF4A inhibitor. The recovery was most significant (close to 100%) after treatment with arsenite combined with adenosine triphosphate (ATP) depletion, while no stress granules formed after treatment with arsenite combined with Pat. Inhibiting its ATP-dependent ribonucleic acid (RNA) binding capacity can relieve the restriction on RNA aggregation, thereby bypassing the G3BP-dependent pathway to promote stress granule formation. These results indicate that EIF4A2 activity is a key factor limiting stress granule formation.

[0053] The method for preparing chiral silica nanoparticles of the present invention is simple, highly controllable, and easy to scale up for production. The prepared nanoparticles have good biocompatibility and immune-activating activity, and can be widely used in the fields of immunotherapy and vaccine adjuvants, with significant industrial practical value and clinical translation prospects.

[0054] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the technical principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for preparing chiral silica nanoparticles, characterized in that, Includes the following steps: (1) Dissolve the structure-directing agent and the chiral inducing agent in deionized water, stir to dissolve, adjust the pH to alkaline, and obtain an aqueous solution; (2) An organic phase is added to the aqueous solution to form a two-phase reaction system; (3) Add silicate ester compounds as silicon sources to the biphase reaction system and react at 50-80°C for 12-24 hours; (4) After the reaction is complete, the product is collected by centrifugation, washed, dried, and calcined to remove the template, and the chiral silica nanoparticles are obtained.

2. The method for preparing chiral silica nanoparticles according to claim 1, characterized in that, The structure directing agent is hexadecyltrimethylammonium bromide; the chiral inducing agent is L-ascorbate glucoside, D-ascorbate glucoside, or a racemic mixture of L-ascorbate glucoside and D-ascorbate glucoside.

3. The method for preparing chiral silica nanoparticles according to claim 1, characterized in that, The organic phase is at least one of cyclohexane, n-hexane, or toluene; the silicate compound is tetraethyl orthosilicate or tetramethyl orthosilicate.

4. A chiral silica nanoparticle prepared by the preparation method according to any one of claims 1-3.

5. The chiral silica nanoparticles according to claim 4, characterized in that, The nanoparticles have a mesoporous structure, a particle size of 200-300 nm, a polydispersity index of less than 0.2, an absolute value of Zeta potential greater than 30 mV, and exhibit a mirror-symmetric Cotton effect in circular dichroism spectroscopy.

6. The use of the chiral silica nanoparticles according to claim 4 or 5 in the preparation of immune activators or vaccine adjuvants.

7. The application according to claim 6, characterized in that, The chiral silica nanoparticles inhibit the function of EIF4A2 protein by chiral-dependent binding, thereby inducing stress particle assembly and activating antigen-presenting cells.

8. The application according to claim 7, characterized in that, The antigen-presenting cells are dendritic cells or macrophages; immune activation is manifested by increased secretion of pro-inflammatory cytokines and / or upregulation of cell surface co-stimulatory molecules and MHC-II molecules.

9. The application according to claim 8, characterized in that, The pro-inflammatory cytokines include at least one of IL-6, IL-1β, TNF-α, IL-12, and IL-18; the cell surface co-stimulatory molecules include CD80 and / or CD86.

10. The use of the chiral silica nanoparticles of claim 4 or 5 in the preparation of medicaments for the treatment and / or prevention of tumors.